N4 Pharma is developing Nuvec, a silica nanoparticle vaccine and cancer therapeutic delivery system. It partners with companies developing antigens to use Nuvec as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity.
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma’s business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programmes, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
N4 Pharma is a publicly traded company (LSE:N4P).